Bizarre how quiet this thread is the day before listing
Anyway, plenty of potential in this little bio IMO: MC: $26m Cash in bank: $10m EV: $16m
Senior Leadership team own ~23% of company. CEO Michael Aldridge has been involved in numerous pharma company exits, ranging from $300M to US $5.6B, Chairman Prof. Jonathan West is a former Assoc. Prof. at Harvard Business School and an advisor to major corporates including DuPont, Roche, Novartis and Syngenta.
The company is looking to address the US $3.7bn Nail Fungal treatment market with >25 million invested in R+D of HXP124 to date. It has been shown to be twice as effective as current topical products, after only six-weeks of treatment. Peak sales for Jublia®, the existing leading topical product in the USA are >US$330m pa.
With 10 mill cash at bank upon listing, the company is well funded through their Phase IIb trials in 2021.
GLTA Holders!
HXL Price at posting:
30.5¢ Sentiment: Buy Disclosure: Held
